```
=> d his full

     (FILE 'HOME' ENTERED AT 15:17:50 ON 22 JUN 2005)

     FILE 'HCAPLUS' ENTERED AT 15:17:56 ON 22 JUN 2005
L1            1 SEA ABB=ON  PLU=ON  (US20050074830 OR US6649362 OR US2002005177
                7)/PN OR (WO98-AU730 OR AU97-9002#)/AP,PRN
                D BIB

     FILE 'REGISTRY' ENTERED AT 15:20:54 ON 22 JUN 2005

     FILE 'HCAPLUS' ENTERED AT 15:20:56 ON 22 JUN 2005
L2              TRA L1 1- RN :        5 TERMS

     FILE 'REGISTRY' ENTERED AT 15:20:57 ON 22 JUN 2005
L3            5 SEA ABB=ON  PLU=ON  L2

     FILE 'WPIX' ENTERED AT 15:20:59 ON 22 JUN 2005
L4            1 SEA ABB=ON  PLU=ON  (US20050074830 OR US6649362 OR US2002005177
                7)/PN OR (WO98-AU730 OR AU97-9002#)/AP,PRN

=> b hcap
FILE 'HCAPLUS' ENTERED AT 15:21:26 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Jun 2005  VOL 142 ISS 26
FILE LAST UPDATED: 21 Jun 2005  (20050621/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d all l1 tot

L1   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2005 ACS on STN
AN   1999:193987  HCAPLUS
DN   130:232524
ED   Entered STN:  25 Mar 1999
TI   A method of modulating cellular activity
IN   Vadas, Mathew; Gamble, Jennifer; Xia, Pu; Barter, Philip; Rye, Kerry-Anne;
     Wattenberg, Brian; Pitson, Stuart
PA   Medvet Science Pty. Ltd., Australia
SO   PCT Int. Appl., 62 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  A61K031-13
     ICS  A61K035-14; A61K038-00
CC   1-12 (Pharmacology)
FAN.CNT 1
     PATENT NO.          KIND   DATE         APPLICATION NO.         DATE
     ---------------     ----   --------     --------------------    --------
```

```
PI   WO 9912533            A1    19990318   WO 1998-AU730        19980908 <--
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
             KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
             NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
             UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2302838            AA    19990318   CA 1998-2302838      19980908 <--
     AU 9889658            A1    19990329   AU 1998-89658        19980908 <--
     AU 757358             B2    20030220
     EP 1011654            A1    20000628   EP 1998-941157       19980908 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2001515857         T2    20010925   JP 2000-510431       19980908 <--
     US 2002051777         A1    20020502   US 2001-977217       20011016 <--
     US 6649362            B2    20031118
     US 2005074830         A1    20050407   US 2003-679485       20031007 <--
PRAI AU 1997-9002          A     19970908  <--
     WO 1998-AU730         W     19980908  <--
     US 2000-508249        A1    20000601
     US 2001-977217        A3    20011016
CLASS
 PATENT NO.      CLASS  PATENT FAMILY CLASSIFICATION CODES
 -------------   -----  ------------------------------------------------
 WO 9912533      ICM    A61K031-13
                 ICS    A61K035-14; A61K038-00
 WO 9912533      ECLA   A61K031/66D10; A61K038/17A2; A61K038/45; A61K038/45+M;
                        C12Q001/34; G01N033/53F                             <--
 US 2002051777   NCL    435/015.000; 424/094.500; 435/069.200
                 ECLA   A61K031/66D10; A61K038/17A2; A61K038/45; A61K038/45+M;
                        C12Q001/34; G01N033/53F                             <--
 US 2005074830   NCL    435/015.000; 435/021.000
                 ECLA   A61K031/66D10; A61K038/17A2; A61K038/45; A61K038/45+M;
                        C12Q001/34; G01N033/53F                             <--
AB   The present invention relates generally to a method of modulating cellular
     activity and agents useful for same.  More particularly, the present
     invention contemplates a method of modulating endothelial cell activity
     and even more particularly endothelial cell adhesion mol. expression.
     Most particularly, the present invention provides a method of treating
     conditions involving inflammatory mechanisms such as coronary heart
     disease by preventing or reducing endothelial cell adhesion mol.
     expression.  One aspect of the invention is administration of an agent
     which modulates one or more components of the sphingosine kinase signaling
     pathway (such as sphingosine kinase or sphingosine-1-phosphate).  The
     inhibitory effect of high-d. lipoproteins (HDL) on the sphingosine kinase
     signaling pathway was determined  A further aspect of the invention is a method
     for detecting sphingosine kinase activity using 33P-ATP and sphingosine in
     the presence of a scintillant.
ST   endothelial cell adhesion mol expression inhibition; sphingosine kinase
     signaling pathway inhibition; coronary heart disease adhesion mol
     modulation
IT   Selectins
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (E-; cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   Transcription factors
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (NF-κB (nuclear factor κB); cellular activity response to
        modulating endothelial cell adhesion mol. expression and sphingosine
        kinase signaling pathway using agents such as HDL in relation to
```

```
      treatment of inflammatory conditions such as coronary heart disease)
IT   Cell adhesion molecules
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (PECAM-1; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions
        such as coronary heart disease)
IT   Cell adhesion molecules
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (VCAM-1; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions
        such as coronary heart disease)
IT   Anti-inflammatory agents
     Signal transduction, biological
        (cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   Cell adhesion molecules
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   Artery, disease
        (coronary; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions
        such as coronary heart disease)
IT   Blood vessel
        (endothelium; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions
        such as coronary heart disease)
IT   Ceramides
     RL: BPR (Biological process); BSU (Biological study, unclassified); MFM
     (Metabolic formation); BIOL (Biological study); FORM (Formation,
     nonpreparative); PROC (Process)
        (formation; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions)
IT   Lipoproteins
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (high-d., 3; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions
        such as coronary heart disease)
IT   Sphingomyelins
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (hydrolysis; cellular activity response to modulating endothelial cell
        adhesion mol. expression and sphingosine kinase signaling pathway using
        agents such as HDL in relation to treatment of inflammatory conditions)
IT   Scintillation
        (in sphingosine kinase determination; cellular activity response to modulating
        endothelial cell adhesion mol. expression and sphingosine kinase
        signaling pathway using agents such as HDL)
IT   50864-48-7, Sphingosine kinase
     RL: ANT (Analyte); BPR (Biological process); BSU (Biological study,
     unclassified); ANST (Analytical study); BIOL (Biological study); PROC
     (Process)
        (cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   119567-63-4, N,N-Dimethylsphingosine
     RL: BAC (Biological activity or effector, except adverse); BSU (Biological
     study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   26993-30-6, Sphingosine-1-phosphate   142243-02-5, ERK kinase
     RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL
     (Biological study); PROC (Process)
        (cellular activity response to modulating endothelial cell adhesion
        mol. expression and sphingosine kinase signaling pathway using agents
        such as HDL in relation to treatment of inflammatory conditions such as
        coronary heart disease)
IT   133587-41-4
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (in sphingosine kinase determination; cellular activity response to modulating
        endothelial cell adhesion mol. expression and sphingosine kinase
        signaling pathway using agents such as HDL)
RE.CNT  9     THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Emory University; WO 9007571 A 1990 HCAPLUS
(2) Igarashi, Y; US 5466716 A 1995 HCAPLUS
(3) Nicholas, C; US 4766111 A 1988 HCAPLUS
(4) Oncomembrane Inc; WO 9701752 A 1997 HCAPLUS
(5) Sankyo Co Ltd; JP 10101630 A 1998 HCAPLUS
(6) The Biomembrane Institute; EP 0381514 A 1990 HCAPLUS
(7) The Biomembrane Institute; WO 9503039 A 1995 HCAPLUS
(8) The Regents Of The University Of California; WO 9620710 A 1996 HCAPLUS
(9) The Rogosin Institute; WO 8809345 A 1988 HCAPLUS


=> b reg

FILE 'REGISTRY' ENTERED AT 15:21:33 ON 22 JUN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JUN 2005  HIGHEST RN 852656-52-1
DICTIONARY FILE UPDATES:  21 JUN 2005  HIGHEST RN 852656-52-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

*********************************************************************
*                                                                   *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                   *
*********************************************************************
```

```
Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d ide l3 tot

L3   ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   142243-02-5  REGISTRY
ED   Entered STN:  08 Jul 1992
CN   Kinase (phosphorylating), mitogen-activated protein (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   ERK
CN   ERK kinase
CN   Erk receptor tyrosine kinase
CN   ERK/MAP kinase
CN   Extracellular signal-regulated kinase
CN   Extracellular signal-regulated protein kinase
CN   Gene ERK protein kinase
CN   MAP kinase
CN   MAP/ERK kinase
CN   MAPK
CN   Mitogen-activated protein kinase
CN   p43 MAP kinase
CN   p43 Mitogen-activated protein kinase
CN   p45 MAP kinase
DR   133876-94-5, 141349-99-7, 141350-00-7, 141616-09-3
MF   Unspecified
CI   MAN
SR   CA
LC   STN Files:   ADISNEWS, AGRICOLA, BIOBUSINESS, BIOSIS, BIOTECHNO, CA,
       CAPLUS, CEN, CIN, EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             9947 REFERENCES IN FILE CA (1907 TO DATE)
               73 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
            10005 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 2 OF 5  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   133587-41-4  REGISTRY
ED   Entered STN:  03 May 1991
CN   Adenosine 5'-(tetrahydrogen triphosphate-P''-33P) (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C10 H16 N5 O13 P3
CI   COM
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
```



```
               22 REFERENCES IN FILE CA (1907 TO DATE)
               22 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 3 OF 5  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   119567-63-4  REGISTRY
ED   Entered STN:  17 Mar 1989
CN   4-Octadecene-1,3-diol, 2-(dimethylamino)-, (2S,3R,4E)- (9CI)  (CA INDEX
     NAME)
OTHER CA INDEX NAMES:
CN   4-Octadecene-1,3-diol, 2-(dimethylamino)-, [R-[R*,S*-(E)]]-
OTHER NAMES:
CN   D-erythro-N,N-Dimethylsphingosine
CN   Dimethylsphingosine
CN   N,N-Dimethyl-D-erythro-sphingosine
CN   N,N-Dimethylsphingosine
FS   STEREOSEARCH
DR   135467-28-6
MF   C20 H41 N O2
SR   CA
LC   STN Files:   ADISNEWS, BIOSIS, CA, CANCERLIT, CAPLUS, CHEMCATS, CSCHEM,
       IMSDRUGNEWS, IMSRESEARCH, MEDLINE, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.
Double bond geometry as shown.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               94 REFERENCES IN FILE CA (1907 TO DATE)
               94 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 4 OF 5  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   50864-48-7  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   Kinase (phosphorylating), dihydrosphingosine (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   E.C. 2.7.1.91
CN   Kinase (phosphorylating), sphingosine
CN   Sphingoid long chain base kinase
CN   Sphingosine 1-kinase
CN   Sphingosine kinase
MF   Unspecified
CI   MAN
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,
        CASREACT, CIN, EMBASE, PROMT, TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
             318 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             319 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3   ANSWER 5 OF 5  REGISTRY  COPYRIGHT 2005 ACS on STN
RN   26993-30-6  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (2S,3R,4E)-
     (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate), (E)-D-erythro-
     (8CI)
CN   4-Octadecene-1,3-diol, 2-amino-, 1-(dihydrogen phosphate),
     [R-[R*,S*-(E)]]-
OTHER NAMES:
CN   C18-Sphingosine 1-phosphate
CN   D-erythro-Sphingosine-1-phosphate
CN   Sphingosine 1-phosphate
FS   STEREOSEARCH
DR   26993-39-5
MF   C18 H38 N O5 P
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
       CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE, IMSRESEARCH,
       IPA, MEDLINE, PROMT, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.  Rotation (-).
Double bond geometry as shown.
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             969 REFERENCES IN FILE CA (1907 TO DATE)
              14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             971 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> b wpix
FILE 'WPIX' ENTERED AT 15:21:41 ON 22 JUN 2005
COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE LAST UPDATED:            21 JUN 2005      <20050621/UP>
MOST RECENT DERWENT UPDATE:       200539        <200539/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
    PLEASE VISIT:
 http://www.stn-international.de/training_center/patents/stn_guide.pdf <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
    http://thomsonderwent.com/coverage/latestupdates/           <<<

>>> FOR INFORMATION ON ALL DERWENT WORLD PATENTS INDEX USER
    GUIDES, PLEASE VISIT:
    http://thomsonderwent.com/support/userguides/               <<<
```

```
>>> NEW! FAST-ALERTING ACCESS TO NEWLY-PUBLISHED PATENT
    DOCUMENTATION NOW AVAILABLE IN DERWENT WORLD PATENTS INDEX
    FIRST VIEW - FILE WPIFV.
    FOR FURTHER DETAILS: http://www.thomsonderwent.com/dwpifv  <<<

>>> THE CPI AND EPI MANUAL CODES HAVE BEEN REVISED FROM UPDATE 200501.
    PLEASE CHECK:
http://thomsonderwent.com/support/dwpiref/reftools/classification/code-revision/
    FOR DETAILS. <<<

=> d iall l4 tot

L4   ANSWER 1 OF 1  WPIX  COPYRIGHT 2005 THE THOMSON CORP on STN
ACCESSION NUMBER:      1999-229130 [19]   WPIX
DOC. NO. CPI:          C1999-067375
TITLE:                 Modulating cellular activity by modulating sphingosine
                       kinase signaling pathway.
DERWENT CLASS:         B04 K08
INVENTOR(S):           BARTER, P; GAMBLE, J; PITSON, S; RYE, K; VADAS, M;
                       WATTENBERG, B; XIA, P
PATENT ASSIGNEE(S):    (JOHJ) JOHNSON & JOHNSON PHARM RES & DEV LLC; (JOHJ)
                       JOHNSON & JOHNSON RES PTY LTD; (MEDV-N) MEDVET SCI PTY
                       LTD; (JOHJ) JONSON & JOHNSON PHARM RES & DEV LLC;
                       (BART-I) BARTER P; (GAMB-I) GAMBLE J; (PITS-I) PITSON S;
                       (RYEK-I) RYE K; (VADA-I) VADAS M; (WATT-I) WATTENBERG B;
                       (XIAP-I) XIA P; (JOHJ) JOHNSON & JOHNSON RES PTY
COUNTRY COUNT:         83
PATENT INFORMATION:

     PATENT NO      KIND DATE     WEEK    LA    PG MAIN IPC
     ----------------------------------------------------------
     WO 9912533      A1 19990318 (199919)* EN   62 A61K031-13
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL
            OA PT SD SE SZ UG ZW
         W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE
            GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG
            MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG
            US UZ VN YU ZW
     AU 9889658      A  19990329 (199932)
     EP 1011654      A1 20000628 (200035)  EN      A61K031-13
         R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
     JP 2001515857   W  20010925 (200170)       62 A61K045-00
     US 2002051777   A1 20020502 (200234)          A61K038-43<--
     AU 757358       B  20030220 (200326)          A61K031-13
     US 6649362      B2 20031118 (200376)          C12Q001-48<--
     AU 2003204254   A1 20030619 (200461)#         A61K031-13
     US 2005074830   A1 20050407 (200525)          C12Q001-48<--

APPLICATION DETAILS:

     PATENT NO      KIND                   APPLICATION        DATE
     ----------------------------------------------------------------
     WO 9912533      A1                    WO 1998-AU730       19980908   <--
     AU 9889658      A                     AU 1998-89658       19980908
     EP 1011654      A1                    EP 1998-941157      19980908
                                           WO 1998-AU730       19980908   <--
     JP 2001515857   W                     WO 1998-AU730       19980908   <--
                                           JP 2000-510431      19980908
     US 2002051777   A1 Cont of            WO 1998-AU730       19980908   <--
                        Cont of            US 2000-508249      20000601
                                           US 2001-977217      20011016
     AU 757358       B                     AU 1998-89658       19980908
     US 6649362      B2 Cont of            WO 1998-AU730       19980908   <--
                        Cont of            US 2000-508249      20000601
                                           US 2001-977217      20011016
     AU 2003204254   A1 Div ex          AU 1998-89658        19980908
                                        AU 2003-204254       20030519
     US 2005074830   A1 Cont of         WO 1998-AU730        19980908    <--
                        Cont of         US 2000-508249       20000601
                        Div ex          US 2001-977217       20011016
                                        US 2003-679485       20031007

FILING DETAILS:

     PATENT NO       KIND                 PATENT NO
     ---------------------------------------------------
     AU 9889658      A  Based on          WO 9912533
     EP 1011654      A1 Based on          WO 9912533
     JP 2001515857   W  Based on          WO 9912533
     AU 757358       B  Previous Publ.    AU 9889658
                        Based on          WO 9912533
     US 2005074830   A1 Div ex            US 6649362

PRIORITY APPLN. INFO: AU 1997-9002
                      19970908; AU 2003-204254
                      20030519
INT. PATENT CLASSIF.:
           MAIN:      A61K031-13; A61K038-43; A61K045-00; C12Q001-48
       SECONDARY:     A61K031-133; A61K031-661; A61K035-14; A61K038-00;
                      A61K038-45; A61K038-48; A61K051-00; A61P009-10;
                      A61P029-00; C12Q001-42
BASIC ABSTRACT:
     WO    9912533 A UPAB: 20040621
     NOVELTY - Cellular activity in a mammal is modulated by regulating the
     activity of at least one component (I) of a sphingosine kinase (SK)
     signaling pathway.
          DETAILED DESCRIPTION - Cellular activity is controlled by
     administering:
          (a) an agent that modulates (I); or
     (b) (I) itself.
          INDEPENDENT CLAIMS are also included for the following:
          (1) agents (A) that modulate one or more (I) and thus cellular
     activity; and
          (2) detecting an analyte structurally or functionally reactive with a
     lipid by treating the lipid with a radiolabeled analyte or an analyte plus
     a radiolabeled reporter (simultaneously or separately) in presence of a
     scintillant so that a lipid-radiolabel complex forms and excites the
     scintillant which is then detected.
          ACTIVITY - Anti-inflammatory; anti-atherosclerotic.
          MECHANISM OF ACTION - Inhibition of the SK signaling pathway results
     in reduced expression of adhesion molecules, specifically of endothelial
     cell adhesion molecules which are involved in development of
     atherosclerotic plaque. When human umbilical vein endothelial cells were
     stimulated with tumor necrosis factor alpha , a rapid, but transient,
     increase in SK activity was detected, reaching 165% of baseline activity.
     When the cells were pretreated with high-density lipoprotein, both
     amplitude (maximum 150% of baseline) and duration of SK stimulation were
     reduced. Changes in SK activity were paralleled by changes in the levels
     of sphingosine-1-phosphate and downstream events (activation of kinases
     and nuclear translocation of NF-kappaB transcription factor that
     eventually lead to adhesion molecule expression).
          USE - Modulation of cellular activity is used to treat or prevent
     inflammatory disease, specifically coronary heart disease.
          ADVANTAGE - Compounds with SK activity and (ant)agonists of SK can be
     identified in a rapid, high volume assay.
     Dwg.0/8
FILE SEGMENT:         CPI
FIELD AVAILABILITY:   AB; DCN
MANUAL CODES:         CPI: B04-E01; B04-G01; B04-N02; B14-C03; B14-F06; K08-X
```

```
=> b home

FILE 'HOME' ENTERED AT 15:21:51 ON 22 JUN 2005

=>
```